Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

Ling Cai,Hongyu Liu,Fang Huang,Junya Fujimoto,Luc Girard,Jun Chen,Yongwen Li,Yu-An Zhang,Dhruba Deb,Victor Stastny,Karine Pozo,Christin S. Kuo,Gaoxiang Jia,Chendong Yang,Wei Zou,Adeeb Alomar,Kenneth Huffman,Mahboubeh Papari-Zareei,Lin Yang,Benjamin Drapkin,Esra A. Akbay,David S. Shames,Ignacio I. Wistuba,Tao Wang,Jane E. Johnson,Guanghua Xiao,Ralph J. DeBerardinis,John D. Minna,Yang Xie,Adi F. Gazdar
DOI: https://doi.org/10.1038/s42003-021-01842-7
IF: 6.548
2021-03-09
Communications Biology
Abstract:Abstract Small cell lung cancer (SCLC) is classified as a high-grade neuroendocrine (NE) tumor, but a subset of SCLC has been termed “variant” due to the loss of NE characteristics. In this study, we computed NE scores for patient-derived SCLC cell lines and xenografts, as well as human tumors. We aligned NE properties with transcription factor-defined molecular subtypes. Then we investigated the different immune phenotypes associated with high and low NE scores. We found repression of immune response genes as a shared feature between classic SCLC and pulmonary neuroendocrine cells of the healthy lung. With loss of NE fate, variant SCLC tumors regain cell-autonomous immune gene expression and exhibit higher tumor-immune interactions. Pan-cancer analysis revealed this NE lineage-specific immune phenotype in other cancers. Additionally, we observed MHC I re-expression in SCLC upon development of chemoresistance. These findings may help guide the design of treatment regimens in SCLC.
biology
What problem does this paper attempt to address?